GSE169082

Transcriptome Analysis of PBMCs in peripheral blood of patients with RA

Whole-study status Exploratory only

Dataset can inform exploration but is not strong enough for primary analysis.

Whole-study downloads — these do not apply your sample requirements.

Selected cohort requirements

Samples meeting selected requirements: 0 cases / 0 controls

View matching samples

Patient pairs verified in indexed sample metadata: 0

A case/control comparison meeting these requirements is not confirmed.

Counts describe samples, not independent patients. Pair verification uses explicit subject identifiers in indexed sample metadata. Zero verified pairs does not establish that the study is unpaired; reported matched-normal design alone is insufficient.

Summary

The aim of this study was to analyze the expression profile of circRNAs in PBMCs in peripheral blood of patients with RA by next-generation sequencing, and to identify potential markers for early diagnosis and prognosis of RA, and to lay a foundation for further study on the mechanism of this molecule in PBMCs.

Overall design

RNA-seq of PBMCs of RA patients and normal controls. Control samples re-used from GSE120663

Source Evidence

4 sources
Source Contribution Status
GEO

Original dataset metadata, sample metadata, source links, and GEO data availability flags.

Sample records
7 GSM samples
Primary source
recount3

Planned trusted source for processed count availability.

No match found
Expression Atlas

Planned source for curated expression experiment links.

No match found
PubMed

Primary GEO citations and related PubMed articles that mention this dataset.

3 linked publications 3 DOIs

Primary publication

  1. circPTPN22 as a novel biomarker and ceRNA in peripheral blood mononuclear cells of rheumatoid arthritis. Molecular medicine reports, 2021

Related publications

  1. Integrative analysis of lncRNAs in rheumatoid arthritis: from bioinformatics to experimental validation. Clinical and experimental medicine, 2025
  2. Molecular profiling of rheumatoid Arthritis: Expression dynamics of hsa_circ_0092125 and G6PD in an integrative gene expression study. Biochemistry and biophysics reports, 2025
Available

Metadata Quality Components

Analysis Readiness

Review before analysis
97% DE readiness

Contrast completeness

25/25 pts

Both case and control groups are present in the proposed grouping.

Minimum group size

20/20 pts

Each contrast group has at least 2 samples.

Processed data availability

20/20 pts

Processed data is marked available in the GEO index.

Sample decision clarity

15/15 pts

All samples are assigned to a case or control group.

Blocking warnings

7/10 pts

Warnings are present, but none are critical blockers.

Metadata normalization

10/10 pts

Metadata quality is high enough to support downstream handoff.

Blockers

  • Secondary RNA assay context should be analyzed separately from ordinary bulk RNA-seq.

Next Steps

  • Review blockers and update sample grouping or dataset selection before analysis.

Analysis Preparation Checklist

5/6 ready

Group labels reviewed

Needs review

Siftome proposed case and control labels, but no reviewer confirmation is stored yet.

Open the sample grouping CSV and confirm group labels before analysis.

Minimum sample count met

Ready

Both groups meet the minimum of 2 samples.

Confirm whether the cohort is large enough for the intended statistical analysis.

Processed counts available

Ready

Processed data availability is marked true in the GEO index.

Verify that downloaded processed files contain usable count or expression identifiers.

Ambiguous samples handled

Ready

No review-needed or unassigned samples are present in the proposed grouping.

Review the grouping table for biologically meaningful differences that the automated checks may not detect.

Exclusion decisions recorded

Ready

No hard-excluded samples were detected by the current rules.

Record any manual exclusions in the downstream analysis notes.

Source traceability preserved

Ready

The dataset and sample accessions can be traced back to GEO.

Keep GEO accessions with exported metadata.

Bioinformatician Review

Bioinformatician review required

Ask a bioinformatician to review grouping, count availability, exclusions, and design before DE.

Analysis readiness has blockers that must be resolved before DE.

Assay context may require expert handling before DESeq2-style analysis.

Why This Is Ranked Here

Tumor vs normal
Exploratory only Dataset can inform exploration but is not strong enough for primary analysis.

Applied Review Decisions

No active review decisions affect this ranking.

Derived Classifications

  • Disease context Rheumatoid arthritis Disease context came from Normalization rules.
  • Likely case group Rheumatoid arthritis 4 samples
  • Likely control group Healthy control 3 samples

Intent Interpretation

  • Downgrade or exclusion reason Downgraded for tissue search because it is a biofluid cohort. Derived from current-intent ranking reasons.

Ranking Facts

Supporting evidence

  • Comparison: Patient biofluid vs healthy control. Specimen: Biofluid. Comparison suitability: 20%.
  • Prioritized assay: bulk RNA-seq is the active assay expectation.
  • Interpreted disease metadata: Rheumatoid arthritis.
  • Processed data is available for downstream review.
  • External evidence: PubMed links 3 publications; 3 DOIs available: PMID 34184082, PMID 39969652, PMID 40778323.
  • Publication context: circPTPN22 as a novel biomarker and ceRNA in peripheral blood mononuclear cells of rheumatoid arthritis.. Molecular medicine reports, 2021. PMID 34184082. DOI 10.3892/mmr.2021.12256.
  • Publication context: Integrative analysis of lncRNAs in rheumatoid arthritis: from bioinformatics to experimental validation.. Clinical and experimental medicine, 2025. PMID 39969652. DOI 10.1007/s10238-025-01589-z.
  • Publication context: Molecular profiling of rheumatoid Arthritis: Expression dynamics of hsa_circ_0092125 and G6PD in an integrative gene expression study.. Biochemistry and biophysics reports, 2025. PMID 40778323. DOI 10.1016/j.bbrep.2025.102180.

Cautions

  • Downgraded for tissue search because it is a biofluid cohort.
  • Blood, plasma, or serum cohort downgraded because this ranking targets tissue tumor-vs-normal comparisons.
  • Overall score capped because comparison suitability is weak for the selected search intent.
  • Overall score capped because fewer than ten samples limit cohort confidence.
  • Comparison suitability score is below the Phase 1 recommended threshold.

Dataset Warnings

Normalized Fields

41 fields

Sample Group Preview

7 rows shown
Show Hide
Study totals: Case 4 | Control 3 | Unassigned 0 | Excluded 0 | Ambiguous 0 7 rows shown
Group Role Accession Title Source / characteristics Reason
Rheumatoid arthritis Case GSM5176189 RA-1 PBMCs Diagnosis: RA patient; Tissue: Peripheral blood; Cell type: PBMCs Case marker detected.
Rheumatoid arthritis Case GSM5176190 RA-2 PBMCs Diagnosis: RA patient; Tissue: Peripheral blood; Cell type: PBMCs Case marker detected.
Rheumatoid arthritis Case GSM5176191 RA-3 PBMCs Diagnosis: RA patient; Tissue: Peripheral blood; Cell type: PBMCs Case marker detected.
Rheumatoid arthritis Case GSM5176192 RA-C PBMCs Diagnosis: RA patient; Tissue: Peripheral blood; Cell type: PBMCs Case marker detected.
Healthy control Control GSM5176193 Control_1 PBMCs Diagnosis: Normal control; Tissue: Peripheral blood; Cell type: PBMCs Sample-local control marker detected.
Healthy control Control GSM5176194 Control_2 PBMCs Diagnosis: Normal control; Tissue: Peripheral blood; Cell type: PBMCs Sample-local control marker detected.
Healthy control Control GSM5176195 Control_3 PBMCs Diagnosis: Normal control; Tissue: Peripheral blood; Cell type: PBMCs Sample-local control marker detected.

Use as Discovery Cohort

External Validation Finder

Carry Siftome's disease, organism, specimen, assay, data type, and accession into a validation project. Uncertain fields remain Unknown.